AbstractÐIn order to make the ®rst contribution to the elucidation of essential structural features for 5-HT 7 antagonism, a set of thirty 5-HT 7 antagonists were selected from the literature. A pharmacophore model was built using Molecular Modeling studies with Catalyst program. The information contained in this model was validated with new synthesized compounds. #
Introduction
Serotonin (5-hydroxytryptamine, 5-HT) was discovered over 50 years ago 1 and continues to generate interest as one of the most attractive targets for medicinal chemists. Molecular biological data have revealed the existence of fourteen serotonin receptor subtypes, which can be classi®ed in seven families (5-HT 1À7 ).
2 The 5-HT 7 subtype is the most recent addition to the burgeoning family of 5-HT receptors. 3 Although the biological functions of the 5-HT 7 receptor are poorly understood, preliminary evidences suggest that it may be involved in depression, 4 control of circadian rhythms, 5 and relaxation in a variety of vascular smooth muscles. 6 Nevertheless, the therapeutic utility of 5-HT 7 receptor ligands awaits the development of selective agonists and antagonists. During our work only two selective 5-HT 7 receptor antagonists (SB-258719 7 and DR4004 8 ) were discovered, both from a high-throughput screening of compound libraries. In the meantime of editorial revision, Lovell et al. 9 have reported SB-269970 as a new selective antagonist structurally related to SB-258719. Information on the structural requirements of 5-HT 7 ligands is still unknown and its determination is the major aim for developing speci®c compounds. In a rational drug design, identi®cation of the pharmacophore is one of the most important steps, especially when the structure and properties of the bioreceptor remain unknown. Therefore, our aim in this communication is to report the essential structural features for 5-HT 7 antagonism. The validation of the pharmacophore using data of new synthesized compounds suggests consistencies in structural requirements.
Pharmacophore Generation
The study was performed using the software package Catalyst 10 installed on a Silicon Graphics O2 workstation. A set of thirty 5-HT 7 antagonists 7,8,11À17 structurally dierent from a chemical feature standpoint was selected from the reported data as the target training set for Catalyst analysis (Tables 1±4). In cases where the chirality of a stereogenic center was not speci®ed, Catalyst generated and considered alternative stereoisomers. All structures were built de novo using 2D/3-D editor sketcher in Catalyst. Conformational models were calculated using a 15 Kcal energy cuto (minimization convergence criteria during conformational analysis: energy convergence=0.1 Kcal/mol/A Ê , gradient convergence=0.01 Kcal/mol/A Ê ). The number of conformers generated for each substrate was limited to a maximum of 250. All molecules with their associated conformations were regrouped including the biological data (pK i ). Hypothesis generation was performed and twelve hypotheses were obtained using low energy conformers of the molecules in the training set. After assessing all generated hypotheses, the most plausible one was considered the best. The goodness of the structure±activity correlation was estimated by means of r 2 .
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Results
According to the hypothesis generated by catalyst, the minimal structural requirements for 5-HT 7 antagonism consist of an aromatic ring, a basic nitrogen atom (positive ionizable center), a H-bonding acceptor group and a hydrophobic region at 4.9±5.9 A Ê apart from the basic center ( Fig. 1) . For all the molecules in the training set, reasonable low-energy conformers that align on the hypothesis were found. The overall ability of this hypothesis to estimate properly the anities of all molecules within the training set is shown by the good r 2 value between predicted and estimated anities (r 2 =0.921). This pharmacophoric assumption was then validated using new naphtholactam and naphthosultam derivatives (Fig. 2) . Anity data (Table 5 ) suggest consistencies in required structural features.
Compounds 31±45
18 were obtained by treatment of intermediates 46 with the corresponding piperazines and piperidines 47 in the presence of triethylamine and ace- tonitrile (Scheme 1). The reaction of compounds 48 with the appropriate dibromoderivative rendered key intermediates 46. Respective hydrochloride salts of the synthesized compounds were prepared as samples for biological assays.
Target compounds were assessed for in vitro anity at the 5-HT 7 receptor by radioligand binding assays, using [ 3 H]-5-CT in rat hypothalamus membranes 19 (Table 5 ). All the compounds that ®t our pharmacophore model (38±45) show 5-HT 7 anity (pK i >6.5), whereas all inactive derivatives (31±37, pK i < 6.5) lack the hydrophobic moiety situated at a distance of 4.9±5.9 A Ê from the nitrogen atom, required for 5-HT 7 binding. These results support our pharmacophoric hypothesis. In particular, compound 42 (Fig. 2) has been selected as a new lead compound for the search for 5-HT 7 receptor ligands.
Conclusions
The pharmacophore model for 5-HT 7 antagonism described herein represents the ®rst contribution to the rational design of agents acting at this recently identi®ed serotonin receptor. The postulated hypothesis was validated with a series of new naphtholactam and naphthosultam derivatives that exhibit anity for the 5-HT 7 receptor. This study oers structural insight to aid the development of novel 5-HT 7 ligands, which are essential for the knowledge of the (patho)physiological role of this serotonin receptor subtype. 
